Compare Neurocrine Biosciences Inc (NBIX) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.39. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | XDTE | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $185.50 | $44.76 |
52-Week Low | $123.10 | $36.00 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
XDTE trades at $38.60, down 0.5% on the day, with technical indicators showing bearish momentum as moving averages signal selling pressure. The ETF's weekly dividend strategy has generated significant attention, with recent payouts ranging from $0.09 to $0.26 per share. However, financial ratios remain unavailable, limiting fundamental analysis. Recent news coverage highlights concerns about the sustainability of XDTE's high yield strategy and fee structure compared to alternatives.
The outlook for XDTE appears cautious due to questions about dividend sustainability and competitive fee pressures. While the weekly income strategy attracts yield-seeking investors, structural risks and bearish technical signals suggest limited near-term upside potential. Investors should weigh the high distribution yield against potential total return underperformance in rising markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
